Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.78 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.78 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.78 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.78 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.78 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.78 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | DDX6 | P26196 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | CSK | P41240 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | PLK1 | P53350 | 1/20 | 0.65 |
| ▸ | PRKDC | P78527 | 1/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.65 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909993 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL910346 | 0.91 | PIK3CB (0.85) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL24713829 | 0.90 | PIK3CB (0.81) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL909705 | 0.88 | PIK3CB (0.83) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL29358326 | 0.87 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL902952 | 0.87 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL24713656 | 0.87 | PIK3CB (0.84) | PIK3CBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL29826300 | 0.87 | PIK3CB (0.84) | PIK3CBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL24713655 | 0.87 | PIK3CB (0.84) | PIK3CBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL23482795 | 0.86 | PIK3CB (0.83) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4646626-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | claimed |
| JP-2006500361-A | — | — | 2006-01-05 | — | — | JP | claimed |
| EP-1537102-A1 | INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA | Kinacia Pty Ltd. (AU) | 2005-06-08 | — | — | EP | claimed |
| WO-2004016607-A1 | INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA | KINACIA PTY LTD. (AU) | 2004-02-26 | — | — | WO | claimed |
| WO-2022164812-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-7872011-B2 | Inhibition of phosphoinositide 3-kinase β | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7598377-B2 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2009-10-06 | — | — | US | disclosed |
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | KINACIA PTY. LTD. (AU) | 2008-12-25 | — | — | US | disclosed |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | disclosed |
| EP-1537102-A1 | INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA | Kinacia Pty Ltd. (AU) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004016607-A1 | INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA | KINACIA PTY LTD. (AU) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | PI4KB, PI4KA, PI4K2B | PIK3CB 4/4885PIK3CA 11/4885PIK3CD 8/4885 |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | PI4KA, PI4KB, PI4K2B | PIK3CB 8/4885PIK3CA 16/4885PIK3CD 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.